<?xml version="1.0" encoding="UTF-8"?>

<rss version="2.0">
    <channel>
        <image>
            <title>freepatentsonline.com</title>
            <width>141</width>
            <height>131</height>
            <link>http://www.freepatentsonline.com/</link>
            <url>http://www.freepatentsonline.com/images/logo.gif</url>
        </image>
        
        <title>Free Patents Online: Drug, bio-affecting and body treating compositions</title>
        <link>http://www.freepatentsonline.com./rssfeed/rsspat514.xml</link>
        <description>USPTO Class 514 Drug, bio-affecting and body treating compositions</description>
        <language>en-us</language>
        <lastBuildDate>Tue, 29 Dec 2009 08:00:00 EST</lastBuildDate>
        <item>
            <title><![CDATA[Alkynl and azido-substituted 4-anilinoquinazolines]]></title>
            <link>http://www.freepatentsonline.com./RE41065.html</link>
            <description><![CDATA[The invention relates to compounds of the formula 
 
 
and to pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Emollients and cosmetic preparations]]></title>
            <link>http://www.freepatentsonline.com./7638662.html</link>
            <description><![CDATA[Compounds of the formula (I):  
 
wherein each of R 1 -R 12  is independently hydrogen or a linear C 1-20  alkyl group each of A 1  and A 2  is a 1, 2 or 3 ring carbon atom wherein A 1  is substituted by R 9  and R 10  and A 2  is substituted by R 11  and R 12 ; and wherein at least one of R 1 -R 12  is a linear alkyl group having from 1 to 20 carbon atoms are emollients for use in cosmetics, lubricants and pharmaceutical preparations.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Substituted cyclohexanones]]></title>
            <link>http://www.freepatentsonline.com./7638651.html</link>
            <description><![CDATA[Disclosed herein are substituted cyclohexanone-based NMDA receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Purifications of pomegranate ellagitannins and their uses thereof]]></title>
            <link>http://www.freepatentsonline.com./7638640.html</link>
            <description><![CDATA[Compositions of purified and biologically active ellagitannins are provided by separation from pomegranate husk using a method of extraction and purification using a solid polymeric adsorbent and the uses of the said compounds.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Dipeptidyl peptidase inhibitors]]></title>
            <link>http://www.freepatentsonline.com./7638638.html</link>
            <description><![CDATA[Pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound with the formula:  
 
where the labeled substituents are as described herein.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Orally available sphingosine 1-phosphate receptor agonists and antagonists]]></title>
            <link>http://www.freepatentsonline.com./7638637.html</link>
            <description><![CDATA[The present invention relates to S1P analogs that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R 11  is C 5 -C 18  alkyl or C 5 -C 18  alkenyl; Q is selected from the group consisting of C 3 -C 6  optionally substituted cycloalkyl, C 3 -C 6  optionally substituted heterocyclic, C 3 -C 6  optionally substituted aryl C 3 -C 6  optionally substituted heteroaryl and; R 2  is selected from the group consisting of H, C 1 -C 4  alkyl, (C 1 -C 4  alkyl)OH and (C 1 -C 4  alkyl)NH 2 ; R 23  is H or C 1 -C 4  alkyl, and R 15  is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Piperidines and related compounds for treatment of alzheimer's disease]]></title>
            <link>http://www.freepatentsonline.com./7638629.html</link>
            <description><![CDATA[Compounds of formula I:  
 
selectively inhibit production of Aβ(1-42) and hence are useful in treatment or prevention of disease associated with deposition of β-amyloid in the brain.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Compositions and methods relating to novel benzodiazepine compounds and derivatives]]></title>
            <link>http://www.freepatentsonline.com./7638624.html</link>
            <description><![CDATA[The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and related compounds and methods of using benzodiazepine derivatives and related compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, and the like.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Galactoside inhibitors of galectins]]></title>
            <link>http://www.freepatentsonline.com./7638623.html</link>
            <description><![CDATA[The present invention relates to novel compounds and the use of said compounds as a medicament, as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably galectin-3.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Antisense IAP nucleobase oligomers and uses thereof]]></title>
            <link>http://www.freepatentsonline.com./7638620.html</link>
            <description><![CDATA[The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Urocortin proteins and uses thereof]]></title>
            <link>http://www.freepatentsonline.com./7638607.html</link>
            <description><![CDATA[A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse CDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn IL Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Transient receptor potential channel TRPM8 and its use]]></title>
            <link>http://www.freepatentsonline.com./7638601.html</link>
            <description><![CDATA[This invention provides novel genes and polypeptides of the transient receptor potential channel family, and use of these genes and polypeptides for the treatment of pain and identification of agents useful in the treatment of pain.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Lytic enzymes and spore surface antigen for detection and treatment of Bacillus anthracis bacteria and spores]]></title>
            <link>http://www.freepatentsonline.com./7638600.html</link>
            <description><![CDATA[Novel bacteriophages of  Bacillus anthracis , the nucleic acids of its genome, nucleic acids comprising nucleotide sequences of open reading frames (ORFs) of its genome, and polypeptides encoded by the nucleic acids, are described. Therapeutic and diagnostic compositions, methods and kits related thereto are also provided.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Polymeric micelles for drug delivery]]></title>
            <link>http://www.freepatentsonline.com./7638558.html</link>
            <description><![CDATA[The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Prostaglandin analog compositions to treat epithelial-related conditions]]></title>
            <link>http://www.freepatentsonline.com./7638557.html</link>
            <description><![CDATA[The present invention relates to the formulation and delivery of prostaglandin analogs to treat epithelial-related condition. In some embodiments, the compositions of the invention are used to stimulate hair growth. In some embodiments, the compositions of the invention are used to restore hair color to depigmented hair.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Freeze-dried product of N-[o-(p-pivaloyloxy benzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate and a process for the manufacture thereof]]></title>
            <link>http://www.freepatentsonline.com./7638556.html</link>
            <description><![CDATA[A method for the preparation of a freeze-dried product of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate dissolved in a mixed solvent of water and ethanol, and the freeze-dried product obtained by the method. According to the present invention, N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glycine monosodium salt tetra-hydrate is dissolved in a small amount of a mixed solvent of water and ethanol, and therefore it is possible to manufacture high-dosage product by freeze-drying.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Photocatalytic nano-crystalline TiO2 thin films, method for preparing the same and use thereof]]></title>
            <link>http://www.freepatentsonline.com./7638555.html</link>
            <description><![CDATA[The preferred embodiments provide for a process for preparing a TiO 2  thin film. The preferred embodiments also provide for TiO 2  thin films prepared by the process herein, and a method of using TiO 2  thin films for killing bacteria and viruses in an environment under ultraviolet irradiation. The TiO 2  thin films according to the invention have higher photocatalytic activity, and can particularly be used to photocatalytically degrade organic pollutants in air to hereby kill bacteria and viruses therein.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents]]></title>
            <link>http://www.freepatentsonline.com./7638554.html</link>
            <description><![CDATA[Compounds useful as chemotherapeutic, chemopreventive, and antiangiogenic agents are provided. The compounds are flavanoids, including flavanones, flavanols, and chalcones. The compounds have the structure of formula (I)  
 
wherein R 1  through R 3  and R 5  through R 11  are defined herein, and α, β and γ are optional bonds, providing that when α is absent, β is present, and when β is absent, α is present. When α is present, preferred R 4  moieties are selected from O, S, NH and CH 2 , and when α is absent, preferred R 4  groups are selected from OH, SH, NH 2  and CH 3 . When γ is present, the preferred R 5  substituent is O, while when γ is absent, the preferred R 5  substituent is OH. Pharmaceutical compositions are provided as well, as are methods of synthesis and use.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Hydroxamates, their manufacture and use as pharmaceutical agents]]></title>
            <link>http://www.freepatentsonline.com./7638553.html</link>
            <description><![CDATA[Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method for increasing the bioavailability of glycopyrrolate]]></title>
            <link>http://www.freepatentsonline.com./7638552.html</link>
            <description><![CDATA[The invention relates to a method of increasing the bioavailability of glycopyrrolate by administration of a therapeutically effective amount of glycopyrrolate without food. The invention also provides a kit comprising a pharmaceutical composition comprising a therapeutically effective amount of glycopyrrolate and a pharmaceutically acceptable carrier, prescribing information including advice regarding the administration of glycopyrrolate without food to improve bioavailability, and a container.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Amino alcohol compounds or phosphonic acid derivatives thereof]]></title>
            <link>http://www.freepatentsonline.com./7638551.html</link>
            <description><![CDATA[A method for the prevention or treatment of an immunology-related disease, which is not rheumatoid arthritis or psoriasis, in a mammal in need thereof which involves administering to the mammal a pharmaceutically effective amount of a compound, a pharmacologically acceptable salt of the compound or a pharmacologically acceptable ester of the compound, wherein the compound is a compound having a formula (Ia):  
 
wherein R 1  and R 2  are each a hydrogen, R 3  is hydrogen; R 4  is C 1 -C 2  alkyl; n is 2; X is ═N—D, wherein D is hydrogen C 1 -C 4  alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH 2  or phenylene; Z is ethylene or trimethylene; R 5  is an unsubstituted C 3 -C 10  cycloalkyl, an unsubstituted C 6 -C 10  aryl, or a C 3 -C 10  cycloalkyl or a C 6 -C 10  aryl substituted with 1 to 3 substituents selected from the group consisting of halogen, lower alkyl, halogeno lower alkyl and lower alkoxy; and R 6  and R 7  are each hydrogen.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Pyrrolic derivatives with histone deacetylase inhibitory activity]]></title>
            <link>http://www.freepatentsonline.com./7638550.html</link>
            <description><![CDATA[The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Mitotic kinesin inhibitors]]></title>
            <link>http://www.freepatentsonline.com./7638549.html</link>
            <description><![CDATA[The present invention relates to dihydropyrrole compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention is also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Spiroindolinone derivatives]]></title>
            <link>http://www.freepatentsonline.com./7638548.html</link>
            <description><![CDATA[There are provided compounds of the general formulas  
 
wherein X, Y, R 1 , R 2 , R 3  and R 4  are as described herein. The compounds exhibit anticancer activity.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Cis-alkoxy-substituted spirocyclic 1H-pyrrolidine-2,4-dione derivatives serving as pesticides]]></title>
            <link>http://www.freepatentsonline.com./7638547.html</link>
            <description><![CDATA[The invention relates to novel cis-alkoxy-substituted spirocyclic 1H-pyrrolidine-2,4-dione derivatives of the formula (I)  
 
     in which A, G, X and Y are as defined in the disclosure, to a plurality of processes for their preparation and to their use as pesticides.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Imidazolyl derivatives]]></title>
            <link>http://www.freepatentsonline.com./7638546.html</link>
            <description><![CDATA[The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Anthelmintic composition]]></title>
            <link>http://www.freepatentsonline.com./7638545.html</link>
            <description><![CDATA[A formulation having triclabendazole in solution. In addition a further anthelmintic may be included. The formulation is made by mixing the abamectin and benzyl alcohol and mixing this with triclabendazole and butyl dioxitol. The mix is then heated to dissolve the active, and allowed to cool at which stage the solution is diluted to volume with PEG 4000.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Dimeric small molecule potentiators of apoptosis]]></title>
            <link>http://www.freepatentsonline.com./7638544.html</link>
            <description><![CDATA[Caspase activity and apoptosis are promoted using active, dimeric Smac peptide mimetics of the general formula M1-L-M2, wherein moieties M1 and M2 are monomeric Smac mimetics and L is a covalent linker. Target cancerous or inflammatory cells are contacted with an effective amount of an active, dimeric Smac mimetic, and a resultant increase in apoptosis of the target cells is detected. The contacting step may be effected by administering to a pharmaceutical composition comprising a therapeutically effective amount of the dimeric mimetic, wherein the individual may be subject to concurrent or antecedent radiation or chemotherapy for treatment of a neoproliferative pathology.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof]]></title>
            <link>http://www.freepatentsonline.com./7638543.html</link>
            <description><![CDATA[The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more thiazolidinone compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and/or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a thiazolidinone compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a thiazolidinone compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a thiazolidinone compound to a non-human animal in an amount sufficient to inhibit CFTR.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method of obtaining 2-amino-6-alkyl-amino-4,5,6,7-tetrahydro-benzothiazoles]]></title>
            <link>http://www.freepatentsonline.com./7638542.html</link>
            <description><![CDATA[A process for preparing 2-amino-6-alkyl-amino-4,5,6,7-tetrahydrobenzothiazoles of formula (I)  
 
wherein the asterisk (*) represents an asymmetric carbon and R 1  is C 1 -C 6  alkyl; and enantiomers and mixtures thereof, and their solvates, hydrates and pharmaceutically acceptable salts. The process involves (a) reacting
 
 
with a secondary amine, optionally in the presence of an acid and a first solvent, to form an enamine; (b) optionally removing the acid and first solvent, and then reacting the enamine with sulfur in the presence of a second solvent; and (c) reacting the previously obtained compound with cyanamide to obtain the formula (I) compound. Pramipexole, a dopamine D-2 agonist, can be made by such process, and is useful for the treatment of Parkinson's disease and schizophrenia.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine]]></title>
            <link>http://www.freepatentsonline.com./7638541.html</link>
            <description><![CDATA[Compounds, compositions, and methods relating to 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine or a pharmaceutically acceptable salt thereof are provided for the treatment of Type II diabetes and other diseases associated with poor glycemic control.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Benzofuran compound and medicinal composition containing the same]]></title>
            <link>http://www.freepatentsonline.com./7638540.html</link>
            <description><![CDATA[The present invention relates to a benzofuran compound of the formula (I)  
 
wherein each symbol is as defined in the description, a pharmaceutically acceptable salt thereof and the like. The compound of the present invention has superior leukotriene inhibitory action, BLT2 competitive inhibitory action, BLT2 blocking action, action for the prophylaxis or treatment of allergy, action for the prophylaxis or treatment of asthma and action for the prophylaxis or treatment of inflammation, and is useful as an agent for the prophylaxis or treatment of diseases such as allergic disease, asthma, inflammation and the like, and other diseases.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[1, 3, 4-oxadiazol-2-ones as peroxisome-proliferator activated receptor delta modulators and their use in the treatment of neurological and metabolic disease]]></title>
            <link>http://www.freepatentsonline.com./7638539.html</link>
            <description><![CDATA[The present invention is directed to 1,3,4-oxadiazalones, i.e., the compounds of formula I and their pharmaceutically acceptable salts, stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein.  
 The compounds of this invention are modulators of PPARdelta and therefore useful as pharmaceutical agents, especially for the treatment of demyelinating diseases and disorders of fatty acid metabolism and glucose utilization such as multiple scleroses.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Pharmaceutically active sulfonyl amino acid derivatives]]></title>
            <link>http://www.freepatentsonline.com./7638538.html</link>
            <description><![CDATA[The present invention is related to sulfonyl amino acid derivatives of formula (I), notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl amino acid derivatives. Said sulfonyl amino acid are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 33. The present invention is furthermore related to novel sulfonyl amino acid derivatives as well as to methods of their preparation.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Pyrazole compounds as transforming growth factor (TGF) inhibitors]]></title>
            <link>http://www.freepatentsonline.com./7638537.html</link>
            <description><![CDATA[Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent inhibitors of transforming growth factor (“TGF”)-  signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer, and fibrotic diseases.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[2-Acylaminothiazole derivative or salt thereof]]></title>
            <link>http://www.freepatentsonline.com./7638536.html</link>
            <description><![CDATA[A 2-acylaminothiazole derivative or a pharmaceutically acceptable salt thereof having an excellent effect of proliferating human c-mpl-Ba/F3 cells and an activity of increasing platelets based on the effect of promoting the formation of megakaryocytic colonies. A compound or a pharmaceutically acceptable salt thereof useful in treating thrombocytopenia.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[4-(aminomethyl)-piperidine benzamides as 5HT4-antagonists]]></title>
            <link>http://www.freepatentsonline.com./7638535.html</link>
            <description><![CDATA[The present invention is concerned with novel compounds of formula (I) having 5HT 4 -antagonistic properties. The invention further relates to methods for preparing such novel compounds, pharmaceutical compositions comprising said novel compounds as well as the use as a medicine of said compounds.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Use of indazole derivatives for the treatment of neuropathic pain]]></title>
            <link>http://www.freepatentsonline.com./7638534.html</link>
            <description><![CDATA[Use of a compound of formula (I), wherein X is CH or N, and when X is CH, R is H, OH, a linear or branched alkyl chain having from 1 to 3 carbon atoms, a linear or branched alkoxy chain having from 1 to 3 carbon atoms, or a halogen atom, and when X is N, R is H, or an acid addition salt thereof with a pharmaceutically acceptable organic or inorganic acid, to prepare a pharmaceutical composition active in the treatment of neuropathic pain.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Dihydro-1[1H]-quinolin-2-one derivatives as RXR agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes]]></title>
            <link>http://www.freepatentsonline.com./7638533.html</link>
            <description><![CDATA[The present invention relates to compounds of Formula (I),  
 
methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating RXR mediated disorders. More particularly, the compounds of the present invention are RXR agonists useful for treating RXR mediated disorders.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[3-aryloxy-8-aza-bicyclo[3.2.1]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors]]></title>
            <link>http://www.freepatentsonline.com./7638532.html</link>
            <description><![CDATA[This invention relates to novel 8-aza-bicyclo[3.2.1]oct-6-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors.  In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists]]></title>
            <link>http://www.freepatentsonline.com./7638531.html</link>
            <description><![CDATA[Disclosed are compounds of the formula  
 
or a pharmaceutically acceptable salt or solvate thereof, wherein:
 
     M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR 5 )—, —C(N—OR 5 )—CH(R 6 )—, —CH(R 6 )—C(N—OR 5 )—, —O—, —OCH 2 —, —CH 2 O— or —S(O) 0-2 —; Y is —O—, —(CH 2 ) 2 —, —C(═O)—, —C(═NOR 7 )— or —SO 0-2 —; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R 1  is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R 2  is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification;
 
compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Inhibitors of Akt activity]]></title>
            <link>http://www.freepatentsonline.com./7638530.html</link>
            <description><![CDATA[The present invention is directed to compounds which contain a five-membered heterocyclic ring fused to a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents]]></title>
            <link>http://www.freepatentsonline.com./7638529.html</link>
            <description><![CDATA[The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid:  
 The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Compositions and methods for targeting cancer cells]]></title>
            <link>http://www.freepatentsonline.com./7638528.html</link>
            <description><![CDATA[The invention includes compositions and methods useful for treatment of a virus infection in a mammal by double-targeting the virus (i.e. targeting the virus at more than one stage of the virus life cycle) and thereby inhibiting virus replication. The compositions of the invention include compounds which comprise a phosphocholine moiety covalently conjugated with one or more antiviral agents (e.g. nucleoside analogue, protease inhibitor, etc.) to a lipid backbone. The invention also includes pharmaceutical compositions and kits for use in treatment of a virus infection in mammals. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to treat the infection, to a mammal infected with a virus. Additionally, the invention includes compositions and methods useful for combating a cancer in a mammal and for facilitating delivery of a therapeutic agent to a mammalian cell. The compositions of the invention include compounds which comprise an alkyl lipid or phospholipid moiety covalently conjugated with an anticancer agent (e.g. a nucleoside analogue). The invention also includes pharmaceutical compositions and kits for combating a cancer and for facilitating delivery of a therapeutic agent to a mammalian cell. The methods of the invention comprise administering a compound of the invention, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of the invention, in an amount effective to combat a cancer or to facilitate delivery of a therapeutic agent to a mammalian cell.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Spirocyclic heterocyclic derivatives and methods of their use]]></title>
            <link>http://www.freepatentsonline.com./7638527.html</link>
            <description><![CDATA[Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism]]></title>
            <link>http://www.freepatentsonline.com./7638526.html</link>
            <description><![CDATA[Disclosed are compounds of the formula:  
 
and compounds of the formula:
 
 
wherein R 1 , R 2 , R 3 , R 4 , R 5 , u and v are as defined herein. Also disclosed are methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol using compounds of formula I or IIA.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Trisubstituted thiophenes as progesterone receptor modulators]]></title>
            <link>http://www.freepatentsonline.com./7638525.html</link>
            <description><![CDATA[The present invention is directed to novel trisubstituted thiophene derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical usage of these compounds are related to hormonal contraception, the treatment and/or prevention of secondary dysmenorrhea, amenorrhea, dysfunctional uterine bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon or prostate. Additional uses of the invention include stimulation of food intake.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Combination therapy for treating hypercholesterolemia]]></title>
            <link>http://www.freepatentsonline.com./7638524.html</link>
            <description><![CDATA[The invention relates to methods for treating hypercholesterolemia and atherosclerosis, and reducing serum cholesterol in a mammal. The methods of the invention comprise administering to a mammal a first amount of a bile acid sequestrant compound which is an unsubstituted polydiallylamine polymer and a second amount of a cholesterol-lowering agent. The first and second amounts together comprise a therapeutically effective amount.  The invention further relates to pharmaceutical compositions useful for the treatment of hypercholesterolemia and atherosclerosis, and for reducing serum cholesterol. The pharmaceutical compositions comprise a combination of a first amount of an unsubstituted polydiallylamine polymer compound and a second amount of a cholesterol-lowering agent. The first and second amounts comprise a therapeutically effective amount. The pharmaceutical compositions of the present invention may optionally contain a pharmaceutically acceptable carrier.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors]]></title>
            <link>http://www.freepatentsonline.com./7638523.html</link>
            <description><![CDATA[Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile]]></title>
            <link>http://www.freepatentsonline.com./7638522.html</link>
            <description><![CDATA[The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them]]></title>
            <link>http://www.freepatentsonline.com./7638521.html</link>
            <description><![CDATA[The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Pyrimidine compounds]]></title>
            <link>http://www.freepatentsonline.com./7638520.html</link>
            <description><![CDATA[Pyrimidone compounds of formula (I):  
 
are inhibitors of the enzyme Lp-PLA 2  and are of use in treating atheroscelerosis.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease]]></title>
            <link>http://www.freepatentsonline.com./7638519.html</link>
            <description><![CDATA[The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with other drugs to treat cardiovascular diseases such as, but not limited to, muscle atrophy, cardiac hypertrophy, heart failure, and primary pulmonary hypertension.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Substituted pyrazole kinase inhibitors]]></title>
            <link>http://www.freepatentsonline.com./7638518.html</link>
            <description><![CDATA[The present invention is directed to novel substituted pyrazole compounds of Formula (I) or a form or composition thereof  
 
and the use thereof as inhibitors of ATP-protein kinase interactions.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[3-Amino-1-arylpropyl azaindoles and uses thereof]]></title>
            <link>http://www.freepatentsonline.com./7638517.html</link>
            <description><![CDATA[The present invention provides compounds of the formula:  
 
or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R 1 , R 2 , R 3 , R a , R b , R c , R d  and R e  are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Agent for therapeutic treatment of optic nerve diseases and the like]]></title>
            <link>http://www.freepatentsonline.com./7638516.html</link>
            <description><![CDATA[The medicament for therapeutic and/or prophylactic treatment of the present invention has a suppressing action on the retinal degeneration induced by transient retinal ischemia, which is verified by the results for suppressing effect on retinal degeneration in transient retinal ischemia eye. Therefore, the medicament of the present invention has a therapeutic and/or prophylactic effectiveness on diseases in optic nerve and the like.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents]]></title>
            <link>http://www.freepatentsonline.com./7638515.html</link>
            <description><![CDATA[The invention relates to tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Pesticidally active phenol derivatives]]></title>
            <link>http://www.freepatentsonline.com./7638514.html</link>
            <description><![CDATA[There are described compounds of formula (I) wherein X 1  and X 2  are each independently of the other fluorine, chlorine or bromine; A 1  and A 2  are, for example, a bond or a C 1 -C 6 alkylene bridge; A 3  is a C 1 -C 6 alkylene bridge; R 1  and R 2  are, for example, halogen, OH, SH, CN, nitro, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 alkyl-carbonyl, C 2 -C 6 alkenyl, C 2 -C 6 haloalkenyl or C 3 -C 6 alkynyl; R, 3  is, for example, H, halogen, OH, SH, CN, nitro, C 1 -C 6 alkyl or C 1 -C 6 haloalkyl; R 4  and R 5  are, for example, H, halogen, cyano, nitro, C 1 -C 6 alkyl or C 1 -C 3 haloalkyl; m is 1 or 2; Y is, for example, O, S, SO or SO 2 ; Q is, for example, O, S, SO or SO 2 ; W is, for example, a bond, O, S, SO, S02, —C(═O)—O— or —O—C(═O)—; T is, for example, a bond, O, S, SO, SO 2 , —C(═O)—O— or —O—C(═O)—; and E is aryl unsubstituted or substituted from one to five times or heterocyclyl unsubstituted or, depending upon the possibilities of substitution on the ring, substituted from one to four times; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtures and/or tautomers, in each case in free form or in salt form, a process for the preparation of those compounds and their use, pesticidal compositions in which the active ingredient has been selected from those compounds and agrochemically acceptable salts thereof, a process for the preparation of those compositions and their use, plant propagation material treated with those compositions, and a method of controlling pests.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Compounds for the treatment of inflammatory disorders]]></title>
            <link>http://www.freepatentsonline.com./7638513.html</link>
            <description><![CDATA[This invention relates to compounds of the Formula (I):  
 
or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, aggrecanase, ADMP, LpxC, ADAMs, TACE, TNF-α or combinations thereof.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Phenylaminopropanol derivatives and methods of their use]]></title>
            <link>http://www.freepatentsonline.com./7638512.html</link>
            <description><![CDATA[The present invention is directed to phenylaminopropanol derivatives of formula I:  
 
or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromyalgia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods and compositions for treating primary and secondary tumors of the central nervous system (CNS)]]></title>
            <link>http://www.freepatentsonline.com./7638511.html</link>
            <description><![CDATA[Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to a mammalian subject suffering from, or at risk of growth of, tumors of the central nervous system. Furthermore, methods for local application of Taurolidine and/or Taurultam and/or a bioequivalent in solution are disclosed using microdialysis methods, irrigation methods, implantion methods and angiographic methods.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders]]></title>
            <link>http://www.freepatentsonline.com./7638510.html</link>
            <description><![CDATA[The present invention relates to the use of a racemate of the compound of formula (1) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said enantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Diene compounds and formulations]]></title>
            <link>http://www.freepatentsonline.com./7638509.html</link>
            <description><![CDATA[The instant invention provides potent antiandrogen compounds, such as 3β-acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1,5-diene-17-ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus, for example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it has been discovered that compounds of the invention are useful in the prevention and treatment of androgen-independent cancers such as androgen-independent prostrate cancer. Finally, inventive compounds may be used to treat antiandrogen induced withdrawal syndrome.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Glucocorticosteroid compound having anti-inflammatory activity]]></title>
            <link>http://www.freepatentsonline.com./7638508.html</link>
            <description><![CDATA[A compound of formula (I):  
 
wherein
 X represents O or S; R 1  represents C 1-6  alkyl, C 3-8  cycloalkyl, C 3-8  cycloalkylmethyl or C 3-8  cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R 1  represents aryl, substituted aryl, heteroaryl or substituted heteroaryl; R 2  represents hydrogen, methyl, which may be in either the α or β configuration, or methylene; R 3  and R 4  are the same or different and each independently represents hydrogen, halogen or a methyl group; and   represents a single or a double bond;
 
or a physiologically acceptable salt or solvate thereof, and
 
pharmaceutical formulations and methods of use thereof.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Compositions for treatment of inflammatory diseases]]></title>
            <link>http://www.freepatentsonline.com./7638507.html</link>
            <description><![CDATA[Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Granular agrochemical composition]]></title>
            <link>http://www.freepatentsonline.com./7638506.html</link>
            <description><![CDATA[Provided is a granular agrochemical composition by which the problems accompanying the prior art granular agrochemical compositions can be overcome, which can be prepared in a simple formulation and by which sustained releasability of the agrochemically active ingredient is obtained so that the load on the environments can be decreased and the chemical damages caused by the agrochemically active ingredient can be alleviated or prevented. The granular agrochemical composition contains an acidic agrochemically active ingredient, a cationic surfactant and a basic substance. Inter alia, a pH of 5 or higher is obtained in a 1% by mass aqueous suspension thereof. Preferably, the acidic agrochemically active ingredient should have a pKa of 2 to 7 and the cationic surfactant should be one which is gelled or exhibits swellability in water.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Organophosphoric derivatives useful as anti-parasitic agents]]></title>
            <link>http://www.freepatentsonline.com./7638505.html</link>
            <description><![CDATA[The present invention relates to novel phosphonic acid compounds having the structural formula (I): wherein: (a) R is a group of 1 to 5 substituents independently selected from the group consisting of fluoro, chloro, bromo, C 1-4  alkoxy, C 1-4  alkyl, hydroxy, formyl, trifluoromethoxy, phenyl, heterocyclic, heterocyclic-substituted methyl, aminomethyl, hydroxy methyl, bromomethyl, sulfonyl chloride, acetyl chloride, nitroso and cyano, (b) R 1  is selected from the group consisting of hydrogen, C 1-7  alkyl, C 3-10  cycloalkyl, aryl, arylalkyl and heterocyclic, and (c) R 2  is selected from the group consisting of hydroxy and hydroxy-protecting groups, and stereoisomer, solvates and salts thereof. These compounds are useful as anti-infectious and anti-parasitic agents, in particular anti-malaria agents.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Hepatitis a viricide]]></title>
            <link>http://www.freepatentsonline.com./7638504.html</link>
            <description><![CDATA[The invention relates to agents which combat the hepatitis A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Small molecule stimulators of neuronal growth]]></title>
            <link>http://www.freepatentsonline.com./7638503.html</link>
            <description><![CDATA[Provided herein are small molecule stimulators of neuronal growth, their preparation, and their use for treatment of neurological disorders. In one embodiment, provided herein are methods of treatment, prevention, or amelioration of a variety of medical conditions associated with neurological disorders using the compounds and compositions provided herein.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Treatment of EBV and KHSV infection and associated abnormal cellular proliferation]]></title>
            <link>http://www.freepatentsonline.com./7638502.html</link>
            <description><![CDATA[A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method of treatment of mitochondrial disorders]]></title>
            <link>http://www.freepatentsonline.com./7638501.html</link>
            <description><![CDATA[In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such as triacetyluridine, or the like. Also provided are methods of reducing or eliminating symptoms associated with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment include those attributable to a deficiency of one or more pyrimidines.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Fused pentacyclic polyethers]]></title>
            <link>http://www.freepatentsonline.com./7638500.html</link>
            <description><![CDATA[Disclosed are polycyclic polyether compounds of formula I and pharmaceutical compositions comprising such compounds.  
 
     wherein R, OR 1 , and R 2  are as defined herein. 
     
 Also disclosed are methods of regulating mucus clearance in a cell, and methods of treating decreased mucus clearance or mucociliary dysfunction.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Hepatitis C virus codon optimized non-structural NS3/4A fusion gene]]></title>
            <link>http://www.freepatentsonline.com./7638499.html</link>
            <description><![CDATA[Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Substances for preventing and treating autoimmune diseases]]></title>
            <link>http://www.freepatentsonline.com./7638498.html</link>
            <description><![CDATA[A substance for preventing, delaying the onset of, or treating one or more than one autoimmune disease, the substance comprising a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for the autoimmune disease. A method for preventing, delaying the onset of or treating an autoimmune disease in a patient comprising selecting a patient who is susceptible to developing the autoimmune disease, who is developing the autoimmune disease or who has the autoimmune disease and administering to the patient one or more than one dose of a polynucleotide construct comprising a polynucleotide sequence encoding the pro-apoptotic protein BAX and encoding one or more than one autoantigen for an autoimmune disease, or comprising a polynucleotide sequence encoding the adenoviral protein E3-GP19k, or comprising a polynucleotide sequence encoding ΔBCL-2.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Antisense IAP nucleobase oligomers and uses thereof]]></title>
            <link>http://www.freepatentsonline.com./7638497.html</link>
            <description><![CDATA[The present invention features nucleobase oligomers that hybridize to IAP polynucleotide, and methods for using them to enhance apoptosis and treat proliferative disorders.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Nucleoside analogs with carboxamidine modified monocyclic base]]></title>
            <link>http://www.freepatentsonline.com./7638496.html</link>
            <description><![CDATA[Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Peptides as solubilizing excipients for transforming growth factor �� proteins]]></title>
            <link>http://www.freepatentsonline.com./7638495.html</link>
            <description><![CDATA[The present invention relates to compositions comprising excipients or solubilizing agents for proteins. The invention relates to the discovery that a peptide derived from the N-terminus extension of the T266 isoform of rhBMP-2 has properties that enhance the solubility of proteins. The invention also relates to methods of resolubilizing a protein that has precipitated, by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2. The invention also relates to methods of increasing the solubility of a protein by contacting the protein with a peptide comprised of the 17 amino acid extension of the T266 isoform of rhBMP-2.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[G-type peptides to ameliorate atherosclerosis]]></title>
            <link>http://www.freepatentsonline.com./7638494.html</link>
            <description><![CDATA[This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Artificial pulmonary surfactant compositions and use of the same]]></title>
            <link>http://www.freepatentsonline.com./7638493.html</link>
            <description><![CDATA[The artificial pulmonary surfactant composition according to the present invention comprises a lipid mixture system containing no protein or peptide or a protein/peptide-lipid mixture prepared by adding a protein or a peptide to the above lipid mixture system. The artificial pulmonary surfactant composition of this invention is useful for RDS and ARDS as well as for the mitigation or prevention of respiratory insufficiencies caused by pneumonia, respiratory difficulties caused by asthma, etc. and it can be prepared at lower costs.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods of upmodulating an immune response with non-activating forms of B7-4]]></title>
            <link>http://www.freepatentsonline.com./7638492.html</link>
            <description><![CDATA[The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Therapies using non-natural amino acids and polypeptides]]></title>
            <link>http://www.freepatentsonline.com./7638491.html</link>
            <description><![CDATA[Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods of affecting feeding and weight in mammals by administration of relaxin-3]]></title>
            <link>http://www.freepatentsonline.com./7638490.html</link>
            <description><![CDATA[Relaxin-3 is found to have feeding-stimulating activity, body weight increasing activity, and fat weight increasing activity when intracerebroventricularly administered to rats through observation of amount of feeding, body weight and fat weight after administration of relaxin-3. This invention includes: a polypeptide having useful effects in stimulating feeding, increasing body weight, and fattening; a therapeutic agent containing the polypeptide; a method of screening for a compound, a substance, or a salt thereof which activates or suppresses a receptor of the polypeptide; a kit for screening; and an agent with a substance which inhibits expression of the polypeptide, such as a feeding-suppressing agent, a therapeutic agent for the treatment of obesity, and a therapeutic agent for the treatment of diabetes.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Modulation of angiogenesis by Bartonella henselae]]></title>
            <link>http://www.freepatentsonline.com./7638489.html</link>
            <description><![CDATA[The present invention relates to  Bartonella henselae  as a component of a pharmaceutical composition for the modulation of the angiogenesis; a nucleic acid molecule that is derived from the gene encoding the  Bartonella henselae  adhesin A protein (BadA), a vector comprising said nucleic acid molecule; a host containing said nucleic acid molecule or said vector; a (poly)peptide encoded by said nucleic acid molecule; a composition comprising  Bartonella henselae  bacteria; a composition comprising aforesaid (poly)peptide; a method for treating a human or animal being in need of the modulation of the angiogenesis, a method for detecting an infection by  Bartonella  in a human or animal being, as well as a method for immunizing a cat.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Use of alpha-glucosidase inhibitors to treat alphavirus infections]]></title>
            <link>http://www.freepatentsonline.com./7638488.html</link>
            <description><![CDATA[The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound α-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an α-glucosidase inhibitor and at least one additional therapeutic agent.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Lactoferrin in the reduction of pain]]></title>
            <link>http://www.freepatentsonline.com./7638487.html</link>
            <description><![CDATA[The present invention relates to methods of using lactoferrin (LF) to reduce pain in conditions associated with severe or intractable pain by administering a composition of lactoferrin either alone or in combination with other therapy for pain.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method for promoting hard tissue formation]]></title>
            <link>http://www.freepatentsonline.com./7638486.html</link>
            <description><![CDATA[Formulations and methods to promote biological processes to form or regenerate new hard tissues such as bones, cartilage, and/or dental tissues are disclosed. The formulation comprising two proteins is administered to enhance biological activities of a hard tissue growth and differentiation factor characterized by specific and selective upregulation and/or extension of the retention time of the intracellular enzymes and signaling molecules that play important roles to proliferate, differentiate, maturate, and/or mineralize the hard tissue forming cells.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Modulating apoptosis]]></title>
            <link>http://www.freepatentsonline.com./7638485.html</link>
            <description><![CDATA[The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for accelerating wound healing by administration of adipokines]]></title>
            <link>http://www.freepatentsonline.com./7638484.html</link>
            <description><![CDATA[Methods for inducing or accelerating a healing process of a damaged skin or skin wounds are described. The methods include administering to the skin cells colonizing the damaged skin or skin wound a therapeutically effective amount of an adipokine, an adipocyte or preadipocyte modulator, adipocytes, preadipocytes, or stem cells, or transforming the skin cells colonizing the damaged skin or skin wound such as to express and secrete an adipokine, thereby inducing or accelerating the healing process of the damaged skin or skin wound.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Cell nucleus-entering compositions]]></title>
            <link>http://www.freepatentsonline.com./7638483.html</link>
            <description><![CDATA[A pharmaceutically acceptable composition and method for entering a cell nucleus utilizes a cell nucleus-entering polypeptide including at least one of amino acid sequence LKKTET (SEQ ID NO:1), amino acid sequence LKKTNT (SEQ ID NO:2) or amino acid sequence KSKLKK (SEQ ID NO:3), or a conservative variant thereof, linked to a physiologically active agent having at least one of therapeutic or diagnostic application in the cell nucleus.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Protein kinase C zeta as a drug target for arthritis and other inflammatory diseases]]></title>
            <link>http://www.freepatentsonline.com./7638482.html</link>
            <description><![CDATA[The present invention is based on the discovery that ζPKC expression is increased in the tissues of arthritis patients as compared to normal individuals. Accordingly, the present invention provides methods of diagnosing, prognosing, and monitoring the course of arthritis in a patient based on increased ζPKC gene expression in arthritic tissue. The present invention further provides compounds that inhibit the expression of ζPKC for use as remedies in the treatment of arthritis, including, but not limited to, inhibitory polynucleotides and polypeptides, small molecules, and peptide inhibitors. In addition, the present invention provides pharmaceutical formulations and routes of administration for such remedies, as well as methods for assessing their efficacy.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Treatment of spinal cord injury]]></title>
            <link>http://www.freepatentsonline.com./7638481.html</link>
            <description><![CDATA[The present invention relates to the treatment of spinal cord injury with a vaccinia virus complement control protein (VCP).]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease]]></title>
            <link>http://www.freepatentsonline.com./7638480.html</link>
            <description><![CDATA[The invention relates to the use of osteoprotegerin for treatment and/or prevention of fibrotic diseases, in particular of scleroderma.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method for generating engineered cells by homologously recombining segments having increased degeneracy]]></title>
            <link>http://www.freepatentsonline.com./7638334.html</link>
            <description><![CDATA[Inhibitors of mismatch repair can be used to generate hypermutable cells and organisms. By inhibiting this process in cells, new cell lines and varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of homologous recombination. These methods are useful for generating targeted loci that can alter the expression profiles of target genes as well as tag exons of a gene with a reporter marker to facilitate the monitoring of a given gene product when the host is grown under different conditions or exposed to biological and chemical entities.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Anthrax vaccine]]></title>
            <link>http://www.freepatentsonline.com./7638333.html</link>
            <description><![CDATA[Using the nontoxic PA protein from  B. anthracis , a method and composition for use in inducing an immune response which is protective against anthrax in subjects is described.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Amyloid ��  protein (globular assembly and uses thereof)]]></title>
            <link>http://www.freepatentsonline.com./7638283.html</link>
            <description><![CDATA[The invention described in this disclosure involves a new composition of matter, amyloid beta-derived dementing ligands (ADDL's). ADDLs consist of amyloid β peptide assembled into soluble globular non-fibrillar oligomeric structures that are capable of activating specific cellular processes. The invention further encompasses methods for assaying the formation, presence, receptor protein binding and cellular activities of ADDLs. The invention further encompasses assay methods and inhibitor molecules for cellular signaling molecules activated by ADDLs. Also described are molecules that block proteins that promote the formation of ADDLs.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer]]></title>
            <link>http://www.freepatentsonline.com./7638270.html</link>
            <description><![CDATA[A novel gene 254P1D6B and its encoded protein, and variants thereof, are described wherein 254P1D6B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 254P1D6B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 254P1D6B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 254P1D6B can be used in active or passive immunization.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Drink composition and a method for composing a drink]]></title>
            <link>http://www.freepatentsonline.com./7638148.html</link>
            <description><![CDATA[The present invention relates to a drink composition comprising active agents, and to a method for composing a drink. Specifically, the invention is directed to a drink composition to be used during long-lasting sports activities demanding constant energy supply and intensive concentration. The drink composition of the invention in characterized in that it contains glucose, fructose, guarana, and a physiologically active amount of a pycnogenol extract. The method of the invention in characterized in that the active agents are individually selected on the basis of the characteristics of the target group, single user and/or conditions of use, said active agents having at least partly complementing actions.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Composition, apparatus and method for skin rejuvenation]]></title>
            <link>http://www.freepatentsonline.com./7638144.html</link>
            <description><![CDATA[A composition including a base and a plurality of abrasive particles. An apparatus including a head, and an applicator coupled to the head, the applicator having dimensions suitable for contacting localized areas of human skin. A method including applying a composition to an area of human skin, the composition comprising a base and a plurality of abrasive particles, and manipulating the composition over the area of human skin with a handle-operated instrument.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Compositions for nasal administration of pharmaceuticals]]></title>
            <link>http://www.freepatentsonline.com./7638138.html</link>
            <description><![CDATA[Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Coccidiosis poultry vaccine]]></title>
            <link>http://www.freepatentsonline.com./7638131.html</link>
            <description><![CDATA[This invention relates to novel  Eimeria  proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Truncated recombinant major outer membrane protein antigen (R56) of Orientia tsutsugamushi strains Karp, Kato and Gilliam and its use in antibody based detection assays and vaccines]]></title>
            <link>http://www.freepatentsonline.com./7638130.html</link>
            <description><![CDATA[A recombinant, refolded non-fusion polypeptide expressed from a truncated r56 gene of the causative agent of scrub typhus,  Orientia tsutsugamushi  for the Karp, Kato and Gilliam strains has been produced. The invention is useful for detecting prior exposure to scrub typhus, screening for and/or identification of at least one infectious strain-similarity (i.e. a Karp-like, Kato-like or Gilliam-like strain) based on its strength of reaction toward a truncated protein and as a component in vaccine formulation sand production of immune globulins for passive prophylaxis and immunity in subjects.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method of enhancing cardiac tissue repair by administering a SFRP polypeptide]]></title>
            <link>http://www.freepatentsonline.com./7638128.html</link>
            <description><![CDATA[A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods of treating pain and inflammation in neuronal tissue using antagonists of IL-31, IL31Ra and/or OSMRb]]></title>
            <link>http://www.freepatentsonline.com./7638126.html</link>
            <description><![CDATA[Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods of treating diseases with activated protein C]]></title>
            <link>http://www.freepatentsonline.com./7638123.html</link>
            <description><![CDATA[Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Methods for human allografting]]></title>
            <link>http://www.freepatentsonline.com./7638121.html</link>
            <description><![CDATA[A method of preparing a human recipient for a graft from a human which includes: administering donor peripheral blood progenitor cells to the recipient, and providing a minimally ablative.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Polyglycerol dimer polyester resins]]></title>
            <link>http://www.freepatentsonline.com./7638116.html</link>
            <description><![CDATA[The present invention relates to a series of novel polyesters that are prepared by crosslinking polyglycerol and dimer acid. The nature of the water loving polyglycerol group as well as the fact that a C-36 fatty diacid is used in preparation of the products results in unique products.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
        <item>
            <title><![CDATA[Method of increasing photosynthesis in plants comprising an exposure thereof to lipochitooligosaccharides and compositions therefor]]></title>
            <link>http://www.freepatentsonline.com./7637980.html</link>
            <description><![CDATA[The present invention relates to agriculture. More particularly, the invention relates to a method of increasing photosynthesis of a plant and more particularly of crop plants. In addition, the invention relates to a method of increasing photosynthesis and/or yield in crop plants, comprising an exposure thereof to lipo-chitooligosaccharides, and compositions therefor. Further, the invention relates to an agricultural composition for enhancing a plant crop photosynthetic rate and/or growth thereof comprising a photosynthetic rate-promoting amount of at least one lipo chitooligosaccharide (LCO) together with an agriculturally suitable carrier and methods using same.]]></description>
            <pubDate>Tue, 29 Dec 2009 08:00:00 EST</pubDate>
        </item>
    </channel>
</rss>